---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024147"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:10:16.134685+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial

## Summary
- Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.
- Cash $12.3M as of June 30, 2025; net loss $2.9M vs $2.4M YoY.
- Independent DMC recommends continue Phase III TIGeR-PaC trial after second interim analysis; 95 patients randomized, 61 events.
- 13 cancer centers approved as customers (up from 5 in Q1); 4 have used device and placed repeat orders.
- Hired Phil Stocton as Senior Director of Sales; launched PanTheR post-marketing registry study.

## SEC filing metadata
- accession: 0001641172-25-024147
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000164117225024147/0001641172-25-024147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000164117225024147/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024147
- JSON: https://secwatch.observer/filing/0001641172-25-024147.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.